Home LiteratureArticle Details
PMID: 10562305 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

The Journal of clinical investigation ·Vol. 104 ·No. 10 ·1999-11-00 ·Pages 1431-9

Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A

Abstract

HIV-specific CD8(+) T cells play a major role in the control of virus during HIV primary infection (PI) but do not completely prevent viral replication. We used IFN-gamma enzyme-linked immunospot assay and intracellular staining to characterize the ex vivo CD8(+) T-cell responses to a large variety of HIV epitopic peptides in 24 subjects with early HIV PI. We observed HIV-specific responses in 71% of subjects. Gag and Nef peptides were more frequently recognized than Env and Pol peptides. The number of peptides recognized was low (median 2, range 0-6). In contrast, a much broader response was observed in 30 asymptomatic subjects with chronic infection: all were responders with a median of 5 peptides recognized (range 1-13). The frequency of HIV-specific CD8(+) T cells among PBMC for a given peptide was of the same order of magnitude in both groups. The proportion of HIV-specific CD8(+)CD28(-) terminally differentiated T cells was much lower in PI than at the chronic stage of infection. The weakness of the immune response during HIV PI could partially account for the failure to control HIV. These findings have potential importance for defining immunotherapeutic strategies and establishing the goals for effective vaccination.

MeSH Terms
Adult Aged Antibody Specificity CD8-Positive T-Lymphocytes/immunology,virology Cells, Cultured Enzyme-Linked Immunosorbent Assay Female Gene Products, env/immunology Gene Products, gag/immunology Gene Products, nef/immunology Gene Products, pol/immunology HIV Antibodies/immunology HIV Infections/immunology HIV Seropositivity/immunology HIV-1/physiology Humans Interferon-gamma/biosynthesis Male Middle Aged Reference Values Virus Replication nef Gene Products, Human Immunodeficiency Virus
Chemicals
Gene Products, env Gene Products, gag Gene Products, nef Gene Products, pol HIV Antibodies nef Gene Products, Human Immunodeficiency Virus Interferon-gamma
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Dalod M
Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, Unité Institut National de la Santé et de la Recherche Médicale (INSERM) 445, Institut Cochin de Génétique Moléculaire, Université René Descartes, 75014 Paris, France.
Dupuis M
Deschemin J C
Goujard C
Deveau C
Meyer L
Ngo N
Rouzioux C
Guillet J G
Delfraissy J F
Sinet M
Venet A
References (46)
46 references, click to expand
  1. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.
    J Clin Invest. 1991 Apr;87(4):1462-6 PMID: 1707063
  2. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.
    J Clin Invest. 1998 Dec 1;102(11):1969-77 PMID: 9835622
  3. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status.
    Clin Immunol Immunopathol. 1993 Oct;69(1):106-16 PMID: 8403538
  4. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection.
    J Acquir Immune Defic Syndr. 1994 Mar;7(3):245-53 PMID: 7906302
  5. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  6. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  7. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.
    Ann Intern Med. 1995 Apr 15;122(8):573-9 PMID: 7887550
  8. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection.
    AIDS. 1995 May;9(5):421-6 PMID: 7639966
  9. Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity.
    J Virol. 1996 Mar;70(3):2022-6 PMID: 8627730
  10. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.
    Nat Med. 1996 Mar;2(3):338-42 PMID: 8612235
  11. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.
    J Exp Med. 1996 Nov 1;184(5):1801-13 PMID: 8920868
  12. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells.
    Immunol Today. 1996 May;17(5):217-24 PMID: 8991383
  13. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia.
    Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254-8 PMID: 8990195
  14. Virologic and immunologic events in primary HIV infection.
    Springer Semin Immunopathol. 1997;18(3):257-66 PMID: 9089948
  15. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.
    J Exp Med. 1998 Dec 21;188(12):2199-204 PMID: 9858506
  16. Viral immune evasion due to persistence of activated T cells without effector function.
    J Exp Med. 1998 Dec 21;188(12):2205-13 PMID: 9858507
  17. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys.
    J Virol. 1999 Feb;73(2):1573-9 PMID: 9882363
  18. Antigen-specific expansion of cytotoxic T lymphocytes in acute measles virus infection.
    J Virol. 1999 Jan;73(1):67-71 PMID: 9847308
  19. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
    J Virol. 1999 Jan;73(1):797-800 PMID: 9847391
  20. Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients.
    Eur J Immunol. 1999 Jan;29(1):38-44 PMID: 9933084
  21. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  22. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    J Infect Dis. 1999 Mar;179(3):527-37 PMID: 9952358
  23. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
    J Immunol. 1999 Feb 1;162(3):1780-8 PMID: 9973442
  24. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
    J Immunol. 1999 Feb 1;162(3):1827-35 PMID: 9973448
  25. Reciprocal control of T helper cell and dendritic cell differentiation.
    Science. 1999 Feb 19;283(5405):1183-6 PMID: 10024247
  26. Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection.
    J Immunol. 1999 Apr 15;162(8):4796-800 PMID: 10202022
  27. Analysis of a successful immune response against hepatitis C virus.
    Immunity. 1999 Apr;10(4):439-49 PMID: 10229187
  28. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys.
    J Immunol. 1999 May 1;162(9):5127-33 PMID: 10227983
  29. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients.
    AIDS. 1999 May 7;13(7):759-66 PMID: 10357374
  30. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.
    J Virol. 1999 Jul;73(7):5509-19 PMID: 10364299
  31. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Nat Med. 1999 Jun;5(6):677-85 PMID: 10371507
  32. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.
    J Virol. 1999 Aug;73(8):6715-20 PMID: 10400769
  33. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
    J Virol. 1999 Aug;73(8):6721-8 PMID: 10400770
  34. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.
    J Virol. 1999 Sep;73(9):7108-16 PMID: 10438796
  35. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
    J Clin Invest. 1999 Sep;104(6):R13-8 PMID: 10491418
  36. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.
    Nature. 1998 Jan 22;391(6665):397-401 PMID: 9450757
  37. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.
    J Exp Med. 1997 Apr 21;185(8):1423-33 PMID: 9126923
  38. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
    J Exp Med. 1997 May 5;185(9):1605-17 PMID: 9151898
  39. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.
    N Engl J Med. 1997 Oct 30;337(18):1267-74 PMID: 9345075
  40. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
    Science. 1997 Nov 21;278(5342):1447-50 PMID: 9367954
  41. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  42. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.
    J Exp Med. 1998 May 4;187(9):1395-402 PMID: 9565632
  43. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection.
    J Clin Invest. 1998 Jun 1;101(11):2559-66 PMID: 9616227
  44. Acute human immunodeficiency virus type 1 infection.
    N Engl J Med. 1998 Jul 2;339(1):33-9 PMID: 9647878
  45. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
    J Infect Dis. 1998 Jul;178(1):61-9 PMID: 9652424
  46. Peptide binding to empty HLA-B27 molecules of viable human cells.
    Nature. 1991 May 2;351(6321):74-7 PMID: 2027387
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1999-11-00
Pages
1431-9
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC409838
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com